Andersen GS

Carr B

Cederberg H

Clissmann C

Cobb J

Esteller M

Nolan JJ

O'Gorman DJ

on behalf of the DEXLIFE Consortium

Oresic M

Thybo T

Walker M

Zorzano A

\ua9 2014 Elsevier Ireland Ltd.The incidence of type 2 diabetes (T2D) is rapidly increasing worldwide and T2D is likely to affect 592 million people in 2035 if the current rate of progression is continued. Today, patients are diagnosed with T2D based on elevated blood glucose, either directly or indirectly (HbA1c). However, the information on disease progression is limited.Therefore, there is a need to identify novel early markers of glucose intolerance that reflect the underlying biology and the overall physiological, metabolic and clinical characteristics of progression towards diabetes.In the DEXLIFE study, several clinical cohorts provide the basis for a series of clinical, physiological and mechanistic investigations in combination with a range of - omic technologies to construct a detailed metabolic profile of high-risk individuals across multiple cohorts.In addition, an exercise and dietary intervention study is conducted, that will assess the impact on both plasma biomarkers and specific functional tissue-based markers.The DEXLIFE study will provide novel diagnostic and predictive biomarkers which may not only effectively detect the progression towards diabetes in high risk individuals but also predict responsiveness to lifestyle interventions known to be effective in the prevention of diabetes

Newcastle University E-Prints

The DEXLIFE study methods: Identifying novel candidate biomarkers that predict progression to type 2 diabetes in high risk individuals

The DEXLIFE study methods: Identifying novel candidate biomarkers that predict progression to type 2 diabetes in high risk individuals

Abstract

Similar works

Full text

Available Versions

Newcastle University E-Prints